Jaebum Choo is a Professor in the Department of Chemistry at Chung-Ang University in South Korea. He earned his Ph.D. from Texas A&M University in 1994. From 1995 to 2019, he served as a faculty member at Hanyang University. In 2015, he was appointed as a Baik Nam Distinguished Professor, acknowledging his outstanding academic accomplishments. In 2016, he served as the President of the Korea Biochip Society, and in 2020, he chaired the Analytical Chemistry Division of the Korean Chemical Society. Currently, Professor Choo holds the position of Vice-President for Research at Chung-Ang University and serves as the Director of the "Center for Nanophotonics-based Biomedical Diagnostics Research Center (ERC)," supported by the National Research Foundation of Korea. He is currently the associate editor of Analyst at the Royal Society of Chemistry and a member of the editorial board for ACS Sensors and Analytical Chemistry at the American Chemical Society. His ongoing research programs focus on developing highly sensitive optical nano-sensor systems for rapid and precise in vitro diagnostics of infectious diseases. Throughout his career, Professor Choo has delivered over 150 invited lectures in the USA, Europe, and Asia. He has published more than 300 research papers in peer-reviewed journals (with ~22,000 citations and an H-index of 76) and has contributed to eight book chapters.
Toward Rapid and Sensitive Point-of-Care Diagnosis of COVID-19 with Nanoplasmonic Sensing Platforms
Tuesday, 19 March 2024 at 11:00
Add to Calendar ▼2024-03-19 11:00:002024-03-19 12:00:00Europe/LondonToward Rapid and Sensitive Point-of-Care Diagnosis of COVID-19 with Nanoplasmonic Sensing PlatformsEmerging Technologies and Paradigms for In Vitro Dx Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
The SARS-CoV-2 pandemic is causing severe social and economic problems worldwide. RT-PCR has been considered the gold standard for detecting SARS-CoV-2 target genes. However, in RT-PCR, the total diagnostic time, including sample preparation, gene amplification, and detection, takes approximately 3-4 hours. Thus, it is critical to shorten the diagnostic time for rapid on-site diagnosis. Various rapid kits for immune diagnosis, using antigen-antibody reactions, have also been developed to shorten the diagnosis time. However, they have not been adopted as the standard diagnostic method due to their poor sensitivity and accuracy. In particular, the "false-negative" problem of commercialized immunodiagnostic kits is recognized as a severe issue that can exacerbate the spread of SARS-CoV-2. To address these issues, we have developed innovative nanoplasmonic assay platforms with a portable Raman reader for rapid and sensitive diagnostics of SARS-CoV-2 in the field. This technique enables the detection of SARS-CoV-2 with a limit of detection (LoD) of less than 5.0 PFU/mL within 15 minutes. The results of this study demonstrate the possibility of clinical application that can significantly improve the detection limit and accuracy of currently commercialized SARS-CoV-2 immunodiagnostic kits.
Add to Calendar ▼2024-03-18 00:00:002024-03-19 00:00:00Europe/LondonEmerging Technologies and Paradigms for In Vitro Dx Europe 2024Emerging Technologies and Paradigms for In Vitro Dx Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2024-03-19 11:00:002024-03-19 12:00:00Europe/LondonToward Rapid and Sensitive Point-of-Care Diagnosis of COVID-19 with Nanoplasmonic Sensing PlatformsEmerging Technologies and Paradigms for In Vitro Dx Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
